Gyre Therapeutics, Inc.GYRENASDAQ
Loading
SG&A Expense Growth Recovery in ProgressRecovering
Percentile Rank71
3Y CAGR-60.9%
5Y CAGR-5.2%
Year-over-Year Change
Year-over-year SG&A expense growth
3Y CAGR
-60.9%/yr
vs +85.6%/yr prior
5Y CAGR
-5.2%/yr
Recent deceleration
Acceleration
-146.5pp
Decelerating
Percentile
P71
Within normal range
vs 5Y Ago
0.8x
Contraction
Streak
1 yr
Consecutive growthRecovering
| Period | Value |
|---|---|
| 2025 | 16.79% |
| 2024 | -2.90% |
| 2023 | 5.88% |
| 2022 | 280.49% |
| 2021 | 16.32% |
| 2020 | 21.91% |
| 2019 | 7.43% |
| 2018 | 23.63% |
| 2017 | 7.89% |
| 2016 | -3.46% |